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Abstract
A novel multiplex real-time PCR assay for concurrent detection of hepatitis viruses was evaluated for its clinical performance
in screening patients with acute hepatitis. A total of 648 serum samples were collected from patients with acute symptoms
of hepatitis. Concurrent detection of nucleic acids of HAV, HBV and HCV was performed using the MagicplexTM HepaTrio
Real-time Detection test. Serum nucleic acid levels of HBV and HCV were also quantified by the CobasH AmpliPrep/CobasH
TaqManH (CAP/CTM) HBV and HCV tests. Patients’ medical records were also reviewed. Concordance rates between the
results from the HepaTrio and the CAP/CTM tests for the detection of HBV and HCV were 94.9% (k= 0.88) and 99.2%
(k= 0.98), respectively. The cycle threshold values with the HepaTrio test were also correlated well with the levels of HBV
DNA (r=20.9230) and HCV RNA (r=20.8458). The sensitivity and specificity of the HepaTrio test were 93.8% and 98.2%,
respectively, for detecting HBV infection, and 99.1% and 100.0%, respectively, for HCV infection. For the HepaTrio test, 21
(3.2%) cases were positive for both HBV and HCV. Among the positive cases, 6 (0.9%) were true coinfections. This test also
detected 18 (2.8%) HAV positives. The HepaTrio test demonstrated good clinical performance and produced results that
agreed well with those of the CAP/CTM assays, especially for the detection of HCV. This assay was also able to detect HAV
RNA from anti-HAV IgM-positive individuals. Therefore, this new multiplex PCR assay could be useful for the concurrent
detection of the three hepatitis viruses.
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Introduction
Hepatitis A, B, and C viruses (HAV, HBV, and HCV) are
common pathogens that cause hepatitis in humans. Approximately
two billion people worldwide have been infected with HBV and
about 350 million suffer from chronic hepatitis B (CHB).
Moreover, about 25% of adults who were infected with HBV
during childhood die from hepatocellular carcinoma (HCC) or
liver cirrhosis [1]. In addition, an estimated three to four million
people worldwide are infected with HCV each year, and 130 to
170 million people are chronically infected with HCV. More than
350,000 people die from HCV-related liver diseases each year [2].
HAV infections, which occur sporadically and in epidemics,
account for an estimated 1.4 million worldwide cases annually [3].
In the United States, the prevalence of anti-HCV antibodies
(anti-HCV) was about 1.6% between 1999 and 2002, which was
an estimated 4.1 million people [4]. The prevalence of HCV
infections was approximately 1% in Korea in 2003, but was 42.3%
and 80.0% among hemophiliacs and intravenous drug users,
respectively [5]. In a previous study, HBV and HCV infections,
respectively, were associated with 68.1% and 15.2% of HCC cases
in men and 69.9% and 18.8% in women [6]. Therefore, HBV and
HCV infections are worrisome public health problems.
In recent years, antiviral therapies for CHB using nucleos(t)ide
analogues and/or interferons have become standard treatments
[7]. Many hepatologists have also treated chronic hepatitis C with
interferon-alpha plus ribavirin, and there have been many efforts
to develop new antiviral agents for the treatment of HCV
infections [8]. Therefore, early and accurate diagnoses of HBV
and HCV infections are essential for effective treatment and
prevention of disease transmission.
HBV and HCV share common modes of transmission, and thus
they can cause coinfection. In some previous studies, HCV
coinfection rates among hepatitis B surface antigen (HBsAg)-
positive individuals ranged from 3% to 18%, varying in the regions
and subjects studied [9–11]. In another study, about 25% of
hepatitis C patients were positive for HBV serologic markers, and
this proportion was nearly six times higher than that of HCV-
uninfected populations [12].
Although there have been some efforts to develop alternative
assays to PCR tests for detecting hepatitis viruses [13–16], the
diagnosis and monitoring of hepatitis B and C are usually based on
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PCR assays. In this context, a multiplex PCR assay for the
concurrent detection of hepatitis viruses would be useful in
screening for hepatitis virus infections as well as in detecting
coinfection with different types of hepatitis viruses. Recently, the
Korea Food and Drug Administration approved a multiplex real-
time PCR test for use as an in vitro diagnostic test for the
concurrent detection of HAV, HBV, and HCV. In this study, we
evaluated the clinical performance of this novel multiplex PCR
assay. We also assessed the clinical performance of this assay in
screening for hepatitis from an independent high-risk population
of blood-borne infections.
Materials and Methods
1. Ethics Statement
The Institutional Review Board (IRB) of Severance hospital
approved this study. Obtaining informed consents from the
enrolled subjects was exempted by the IRB because this study
was retrospectively performed by analyzing medical records and
assaying stored residual specimens that had been requested for
hepatitis virus PCR assays, and no additional specimen was
collected from the subjects.
2. Samples
Between January 2009 and December 2011, a total of 648
serum samples, which were requested for the HBV or HCV PCR
assay, were collected from patients who presented with current or
recent past non-specific symptoms of hepatitis and/or who showed
unexplained abnormal serum levels of liver enzymes but did not
have a previous history of either hepatitis A, B or C at Severance
Hospital, Yonsei University College of Medicine. All the samples
were aliquoted and stored at 270uC within 1 hour after arrival.
Concurrent detection of HAV, HBV, and HCV from all 648
samples was performed using the MagicplexTM HepaTrio Real-
time Detection (HepaTrio) test (Seegene Inc., Seoul, Korea). The
results of previous PCR tests for the respective samples were
blinded during the entire assay process of the HepaTrio test.
3. Multiplex Real-time PCR Assay
The HepaTrio test is a commercial semi-automated nested
multiplex real-time PCR assay, which uses four kinds of
fluorophores for the concurrent detection of amplicons from
HAV, HBV, HCV, and the Whole Process Control material
(WPC). This assay utilizes a unique technology, Dual Priming
Oligonucleotide (DPOTM). The DPO is composed of a longer 59-
segment (stabilizer), a shorter 39-segment (determiner), and a poly
(I) linker that bridges these two segments. The linker generates a
bubble-like structure which itself is not involved in priming, but
separates out the two parts of the primer to assign the two primer
segments to distinct annealing properties: stable priming and
target-specific extension. This allows blocking of extension of non-
specifically primed templates and improves the PCR specificity
[17,18]. The target of the primers for the amplification of HAV
and HCV is 59-untranslated regions (UTR), which are known to
be highly conserved among the genotypes, especially genotypes 1
to 6 in the case of HCV, and the target region of HBV is N-
terminal of S gene, which is also known as highly conserved along
with genotypes A to H and unrelated with drug resistance
mutations of HBV.
Nucleic acids were eluted from 500 mL of sample to 100 mL of
solution using the MICROLABH STARlet automated purification
system (Hamilton Company USA, Reno, NV, USA). Reverse
transcription PCR comprising 45 cycles was performed using the
MagicplexTM HepaTrio Amplification kit (Seegene, Inc.) and the
amplified products were analyzed by 20 cycles of real-time PCR
using the MagicplexTM HepaTrio Real-time Detection kit
(Seegene Inc.) and the CFX96TM Real-Time PCR Detection
System (Bio-Rad Laboratories, Inc., Hercules, CA, USA). The
fluorescene signal from PCR amplification was automatically
interpreted to the result by using the CFX ManagerTM software
version 2.1 (Bio-Rad Laboratories, Inc.) based on the pre-assigned
experiment protocol and cutoff cycle threshold values (Ct)
suggested by the manufacturer as 10.0, 14.0, and 12.0, respec-
tively, for HAV, HBV, and HCV. Samples showing Ct of equal or
less than these values were regarded as positive for the nucleic
acids of the respective viruses. To ensure that all assay processes
were properly performed, the WPC provided with the assay kit
was added to the samples before the nucleic acid extraction, and
the results were regarded as valid when the Ct for the WPC was
equal to or less than 5.0. The whole assay process was repeated
when the result for WPC was invalid. Positive and negative control
materials provided with the HepaTrio kits were also included in
each test batch.
4. Viral Load Quantification
Levels of HBV DNA and HCV RNA in the same specimens
were quantified using the CobasH AmpliPrep/CobasH TaqManH
(CAP/CTM) HBV Test v2.0 and the CAP/CTM HCV test
(Roche Molecular Diagnostics, Pleasanton, CA, USA), respective-
ly, which are fully automated real-time PCR assays. All assays
were performed according to the manufacturer’s instructions. The
lower and upper detection limits of the CAP/CTM HBV test are
20 IU/mL and 1.76108 IU/mL HBV DNA, respectively, and
those of the CAP/CTM HCV test are 15 IU/mL and
6.96107 IU/mL HCV RNA, respectively. Results below the
lower detection limits were considered negative.
5. Other Assays
HBsAg, antibodies to HBsAg (anti-HBs) and antibodies to HBV
core antigen (anti-HBc) in a serum sample were detected using an
ARCHITECTH i4000SR analyzer with respective assay reagents
(Abbott Laboratories, Abbott Park, IL, USA). Anti-HCV was
detected using the CobasH e 411 automated immunoassay
analyzer with the ElecsysH Anti-HCV reagent kit (Roche
Diagnostics GmbH, Mannheim, Germany). The presence of
IgM antibodies to HAV (anti-HAV IgM) in a sample was
determined using the VitrosH 3600 Immunodiagnostic System
with an anti-HAV IgM reagent kit (Ortho-Clinical Diagnostics,
Johnson & Johnson Co., Buckinghamshire, UK). Serum levels
(IU/L or mg/dL) of aspartate aminotransferase (AST), alanine
aminotransferase (ALT), alkaline phosphatase (ALP) and total
bilirubin were measured by the Hitachi 7600 DDP modular
chemistry analyzer (Hitachi High-Technologies Co., Tokyo,
Japan). Normal upper reference limits for AST and ALT in our
laboratory were 34 and 46 IU/L, respectively. HCV genotypes
were determined by the LINEAR ARRAY HCV Genotyping test
(Roche Molecular Diagnostics).
6. Diagnostic Accuracy Criteria
The ‘diagnostic accuracy criteria’ [19], used to determine
whether patients were infected with HBV or HCV, were based on
following criteria. When the results of the HepaTrio and the
CAP/CTM tests for HBV or HCV were concordant, they were
regarded as true-positive or -negative. When there were discrep-
ancies between the HepaTrio and CAP/CTM test results, the true
diagnosis was determined by retrospective blind review of the
patient’s medical records, including assessment of repetitive
serologic and PCR test results between one month before and
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after sample collection. Patients were considered uninfected with
HBV when they were repetitively negative for HBsAg and HBV
DNA and either positive for anti-HBs or negative for anti-HBc
along with normal serum aminotransferase levels. The patients
were also considered uninfected with HCV when the anti-HCV
assays as well as follow-up CAP/CTM HCV tests were all
repetitively negative along with normal serum aminotransferase
levels. When a patient could not be classified based on the
serologic and PCR test results, the diagnosis was determined to be
‘indeterminate’ and was excluded from estimating clinical
performance.
7. Validation of the Clinical Performance of the HepaTrio
Test
To validate the clinical performance of the HepaTrio test for
detecting HBV and HCV infections from a population with high
risk of blood-borne infections, a total of 100 serum samples were
collected from sequential patients who visited Severance Hospital
to receive regular hemodialysis between January and February
2012. All the samples were assayed using the HepaTrio test.
Retrospective blind reviews of the medical records for all those
patients were performed. A patient was regarded as having true
HBV infection when a sample drawn between one month prior
and after the sample collection for this study was positive for HBV
DNA by the CAP/CTM HBV test, at the same time, HBsAg and
anti-HBs were respectively positive and negative two or more
times. Patients were considered to be not infected with HBV either
when two or more of the HBsAg and anti-HBs assays were
negative and positive, respectively, concurrent with normal serum
aminotransferase levels, or when two or more of the HBsAg and
anti-HBc assay results were all negative and serum aminotrans-
ferase levels were normal during the most recent three months.
A patient was defined as having true HCV infection if HCV
RNA was detected by the CAP/CTM HCV test in a sample
collected during one month before and after the specimen used in
this study was drawn, concurrent with two or more positive results
on anti-HCV assays. The patients were regarded as uninfected
with HCV when two or more results of the anti-HCV assay were
negative during the most recent three months, with normal serum
aminotransferase levels.
8. Statistical Analysis
Analyse-it Method Evaluation Edition version 2.27 software
(Analyse-it Software Ltd., City West Business Park, Leeds, UK)
was used for all statistical analyses. The concordance rate and
kappa coefficient (k) with its 95% confidence interval (CI) were
calculated to estimate the concordance between the results of
different assays. Correlation coefficients (r) between the Ct
obtained by the HepaTrio test and viral loads quantified by the
CAP/CTM assays were assessed by the Spearman’s rank test.
Sensitivities, specificities and their respective 95% CIs were
calculated based on the ‘diagnostic accuracy criteria’ described
above. Pairwise comparison of HCV RNA levels between the
HCV genotype groups were performed using Kruskal-Wallis test
with Bonferroni correction to compensate alpha statistical error
from multiple comparisons. A P-value of less than 0.05 was
considered significant.
Results
1. Subject Characteristics
The total of 648 patients suspected of having acute hepatitis
included 340 males (52.5%) and 308 females (47.5%). The median
age of the subjects was 54.1 years (first to third quartiles, 42.1 to
65.0 years). Median serum levels of ALT, AST, ALP and total
bilirubin at the patient’s first visit were 112.0 IU/L (first to third
quartiles, 66.0 to 227.3 IU/L; maximum 7,827 IU/L), 94.0 IU/L
(first to third quartiles, 56.7 to 192.0 IU/L; maximum 9,423 IU/
L), 70.0 IU/L (first to third quartiles, 56.9 to 94.0 IU/L;
maximum 427 IU/L), and 0.9 mg/dL (first to third quartiles,
0.6 to 1.3 mg/dL; maximum 28.1 mg/dL), respectively.
Infections with one or more types of hepatitis virus were
identified in all subjects (Figure 1). The median HBV DNA
concentration in the 194 cases of true HBV infection was
2.356104 IU/mL (first to third quartiles, 6.136102 to
1.756107 IU/mL), and the median Ct in the HepaTrio test was
4.89 (first to third quartiles, of 3.66 to 7.27). In addition, the
median level of HCV RNA in the 459 cases of true HCV infection
was 1.516106 IU/mL (first to third quartiles, 2.046105 to
5.326106 IU/mL), and the median Ct in the HepaTrio test for
these patients was 4.15 (first to third quartiles, 3.56 to 4.88).
Among the HCV infection cases, 311 samples were genotyped for
HCV, and 163 (52.4%), 133 (42.8%), and 15 (4.8%) of them were
genotype 1, 2, and 3, respectively. Median HCV RNA level of
cases infected with HCV genotype 1 was 2.456106 IU/mL (first
to third quartiles, 6.546105 to 6.326106 IU/mL) and was higher
than those with genotype 2 (median, 9.786105 IU/mL; first to
third quartiles, 1.256105 to 3.736106 IU/mL; P=0.0006) and
genotype 3 (median, 1.246105 IU/mL; first to third quartiles,
4.886104 to 2.856105 IU/mL; P,0.0001). HCV RNA levels
were also higher in genotype 2 infections than in genotype 3
infections (P=0.0195).
2. Concordance between the Test Results
Agreement between the results from the HepaTrio and the
CAP/CTM tests is presented in Table 1. The results from the
HepaTrio test for detecting HBV DNA or HCV RNA agreed with
those from the CAP/CTM HBV or HCV test in 94.9% and
99.2% of all 648 cases, respectively. Detailed results for the
discrepant cases between the CAP/CTM and the HepaTrio tests
are summarized in Table 2.
Figure 2 illustrates the correlation between the Ct from the
HepaTrio test and viral load quantified by the CAP/CTM assays.
The Ct from the HepaTrio test was inversely correlated with the
serum level of HBV DNA (r=20.9230) and HCV RNA
(r=20.8458).
3. Clinical Performance of the Tests
According to the above-mentioned diagnostic accuracy criteria,
all enrolled subjects were classified as true or false HBV and HCV
infections, or indeterminate cases (Figure 1). The sensitivity and
specificity of the HepaTrio test were 93.8% and 98.2%,
respectively, for detecting HBV infections, after excluding the
indeterminate cases (Table 3), and were 99.1% and 100.00%,
respectively, for detecting HCV infection. The CAP/CTM HBV
test showed a sensitivity of 98.5% and a specificity of 99.3% for
detecting HBV infection in the same samples. The CAP/CTM
HCV assay also demonstrated 100.0% sensitivity and specificity
for the diagnosis of HCV infections (Table 3).
4. Detection of HBV and HCV Coinfection
The cases in which HBV DNA and HCV RNA were
concurrently detected by either or both the HepaTrio and the
CAP/CTM assays are summarized in Table 4. The HepaTrio test
identified 21 such cases (3.2% of all 648 specimens), and six (0.9%)
of them were true coinfections (median Ct for HBV DNA, 9.74;
median Ct for HCV RNA, 5.65), and the other seven were false
positives for HBV DNA with a median Ct of 13.29 (median Ct for
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HCV RNA, 3.59). HBV and HCV coinfection could not be
identified by reviewing the medical records of the remaining eight
patients (median Ct for HBV DNA, 12.54; median Ct for HCV
RNA, 4.62) (Table 4).
The CAP/CTM HBV and HCV assays yielded eight (1.2%
among all 648 cases) results in which HBV DNA and HCV RNA
were concurrently detected. Among them, four were true
coinfections (median HBV DNA, 1.526103 IU/mL; median
HCV RNA, 5.826106 IU/mL) and the other two were false
positives for HBV DNA with results of 225 and 507 IU/mL (HCV
RNA, 1.536106 and 1.196104 IU/mL, respectively). HBV and
HCV coinfection could not be determined for the remaining two
patients (HBV DNA of 22.0 and 77.8 IU/mL, HCV RNA of
5.766104 and 1.176107 IU/mL) (Table 4).
In addition, 7 (26.9%) out of 25 cases in which both HBV DNA
and HCV RNA were detected by the HepaTrio test and/or by the
CAP/CTM assays were true HBV and HCV coinfection, and
both the HepaTrio and CAP/CTM tests concurrently indicated
coinfection in only three of the seven cases.
5. Detection of HAV by the HepaTrio Test
The HepaTrio test detected 18 (2.8% among all 648 cases)
positives for HAV RNA (Figure 1), and all of those cases were anti-
HAV IgM-positive, except one in which HAV IgM was not
Figure 1. Results of the HepaTrio and the CobasH AmpliPrep/CobasH TaqManH (CAP/CTM) HBV and HCV tests. For discrepant cases
between the HepaTrio and the CAP/CTM tests, medical records including the results of serologic tests were reviewed. TP, true positive; FN, false
negative; FP, false positive; TN, true negative.
doi:10.1371/journal.pone.0049106.g001
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assessed. Most of the HAV RNA-positive cases (16 of 18, 88.9%)
were acute HAV infection in chronic HBV carriers. The median
Ct for HAV RNA in those 18 cases was 4.59, and signals from the
amplification of HAV RNA were not detected in any of the
remaining 630 samples (Ct.20.0).
6. Validation of the Clinical Performance of the HepaTrio
Test
A total of 100 samples from hemodialysis patients, which
consisted of 53 males and 47 females, were assayed by the
HepaTrio test. Median age of the patients was 58.5 years (first to
third quartiles, 51.0 to 69.0 years) and median hemodialysis period
was 51.5 months (first to third quartiles, 30.8 to .66.0 months).
For this patient group, the clinical performance of the HepaTrio
test is summarized in Table 5. The prevalence of HBV and HCV
infections was 3.0% and 6.0%, respectively, and there were no
HBV and HCV coinfections or HAV infection cases. The median
Ct on the HepaTrio test for the three true HBV and six true HCV
infection cases was 4.85 and 2.48, respectively. There were seven
false positive cases for HBV infection with a median Ct of 9.60,
but no false negative cases were found. In addition, there was one
false negative case for HCV infection (Ct.20.0), but no false
positives.
Discussion
In this study, we evaluated the clinical performance of a novel
multiplex real-time PCR assay, which was designed to simulta-
neously detect HAV, HBV and HCV. Although there have been
some studies on multiplex assays for the concurrent detection of
HBV, HCV, and human immunodeficiency virus, which are
major targets in screening tests for donated blood [20–25], there
has been no real-time PCR assay for the concurrent detection of
the three common hepatitis viruses. In a study, a flow-cytometric
microsphere-based hybridization assay after reverse-transcription
Table 1. Agreement between the results of the HepaTrio test and the CAP/CTM HBV and HCV assays.
HepaTrio
Target
virus CAP/CTM Negative Positive Total Concordance rate (%) Kappa coefficient 95% CI P-value
HBV Negative 436 17 453
Positive 16 179 195
Total 452 196 648 94.91 0.8791 0.8390 to 0.9193 ,0.0001
HCV Negative 188 1 189
Positive 4 455 459
Total 192 456 648 99.23 0.9814 0.9652 to 0.9976 ,0.0001
Abbreviations: CAP/CTM, CobasH AmpliPrep/CobasH TaqManH; HBV, hepatitis B virus; HCV, hepatitis C virus; CI, confidence interval.
The overall concordance rate between the results from the HepaTrio and the CAP/CTM assays for the detection of HBV along with HCV was 94.14%.
doi:10.1371/journal.pone.0049106.t001
Table 2. Summary of discrepant cases between the HepaTrio and the CAP/CTM assays.
HBV HCV Serologic testsa PCRb Final diagnosis
Discrepancy
in
N (%)
of cases
CAP/
CTM HepaTrio
CAP/
CTM HepaTrio
HepaTrio
HAV HBsAg Anti-HBc Anti-HBs
Anti-
HCV
Anti-
HAV IgM HBVHCV HBVHCV HAV
HBV 2 (0.31) Pos Neg Neg Neg Neg Pos Pos Neg Neg Neg or NT Pos NT Pos Neg Neg
1 (0.15) Pos Neg Pos Pos Neg Neg Pos Neg Pos NT Pos Pos Pos Pos Neg
9 (1.39) Pos Neg Neg Neg Pos Pos Pos Neg Neg Pos Pos NT Pos Neg Pos
3 (0.46) Neg Pos Pos Pos Neg Neg Pos Neg Pos Neg or NT Pos Pos Pos Pos Neg
1 (0.15) Pos Neg Neg Neg Pos Neg Pos Pos Neg Pos NegNT NegNeg Pos
2 (0.31) Pos Neg Pos Pos Neg Neg Pos Pos Pos Neg or NT Neg Pos Neg Pos Neg
7 (1.08) Neg Pos Pos Pos Neg Neg Pos or NT Pos Pos Neg or NT Neg Pos Neg Pos Neg
1 (0.15) Pos Neg Pos Pos Neg NT NT NT Pos NT NT Pos Ind Pos Neg
6 (0.93) Neg Pos Pos Pos Neg Neg or NT NT Pos or NT Pos Neg or NT NT Pos Ind Pos Neg
HCV 2 (0.31) Neg Neg Pos Neg Neg Neg Neg or Pos Pos Pos NT NT Pos Neg Pos Neg
1 (0.15) Neg Neg Pos Neg Pos NT NT NT Pos NT NT Pos Neg Pos Pos
1 (0.15) Pos Pos Neg Pos Neg Pos Pos Neg NT NT Pos NT Pos Ind Neg
HBV and HCV 1 (0.15) Neg Pos Pos Neg Neg Neg Neg Pos Pos Neg NegPos NegPos Neg
Abbreviations: CAP/CTM, CobasH AmpliPrep/CobasH TaqManH; HBV, hepatitis B virus; HCV, hepatitis C virus; HAV, hepatitis A virus; PCR, polymerase chain reaction; Pos,
positive; Neg, negative; NT, not tested; Ind, indeterminate.
aSerologic test results between one month before and after sample collection were referenced when the results were consistent at two or more separated time points.
bFollow-up CAP/CTM HBV or HCV tests within a month.
doi:10.1371/journal.pone.0049106.t002
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PCR was developed, and the assay provided a sensitive and
specific concurrent detection of HIV, HBV, and HCV from 35
serologically well-established clinical specimens as well as from 20
seronegative blood donor plasma samples [20]. Another study
reported that an automated multiplex real-time PCR assay system
demonstrated 0.34% of false-positive rate in the concurrent
detection of HIV, HBV, and HCV from 55,537 pooled blood
donor plasma samples [21]. A qualitative visual DNA chip method
combined with multiplex and nested PCR was also developed for
the detection of the same three viruses and this assay showed an
analytical sensitivity of around 1 pg of viral DNA [22]. More
recently, another assay utilizing transcription-mediated amplifica-
tion (TMA) and chemiluminescent detection principles demon-
strated a specificity of greater than 99% in the detection of the
three viruses from 740 seronegative samples [25]. Although these
assays utilized different methods, reports on the assays mainly
focused on the evaluation of the specificity and analytical
sensitivity, since they were developed for screening donated blood.
Meanwhile, our study’s main focus was on the evaluation on the
clinical sensitivity and specificity of the new multiplex real-time
PCR assay using clinical samples.
Since the efficacies of methods for amplifying DNA and RNA
from different viruses would be hard to equalize, developing a
multiplex PCR assay could be very challenging. The HepaTrio
test is novel in that it is performed by multiplex reverse
transcription real-time PCR to detect the three common hepatitis
viruses. This assay utilizes two distinctive features, the Real
Amplicon Detection (READ) and the previously mentioned DPO
technology. The READ is a type of real-time PCR which utilizes a
different technique from conventional fluorescence detection
methods used in other real-time PCR assays. The manufacture
of the HepaTrio suggests that the READ technology enables early
detection of amplicons, thus the Ct from the HepaTrio tests in our
data was generally lower than that from a conventional real-time
Figure 2. Correlation between cycle threshold (Ct) values on the HepaTrio test and viral concentrations. A. Serum levels of HBV DNA,
which were quantified by the CobasH AmpliPrep/CobasH TaqManH (CAP/CTM) HBV assay, correlated well with Ct values on the HepaTrio test (n = 648,
r=20.9230, 95% confidence interval [CI] =20.9336 to20.9107, P,0.0001). B. The correlation coefficient between Ct values on the HepaTrio test and
serum HCV RNA concentrations measured by the CAP/CTM HCV assay was 20.8458 (n = 648, 95% CI =20.8663 to 20.8223, P,0.0001). Filled red
circles represent individual values and straight blue lines denote cutoff Ct values of the HepaTrio or lower detection limits of the CAP/CTM assays. ND,
not detected.
doi:10.1371/journal.pone.0049106.g002
Table 3. Sensitivities and specificities of the HepaTrio test and the CAP/CTM assays for detecting HBV and HCV infections.
Target virus Assay Sensitivity (%) 95% CI (%) Specificity (%) 95% CI (%)
HBV CAP/CTM HBVa 98.45 95.55 to 99.68 99.33 98.05 to 99.86
CAP/CTM HBVb 98.46 95.57 to 99.68 99.34 98.08 to 99.86
HepaTrioa 93.81 89.44 to 96.76 98.21 96.50 to 99.22
HepaTriob 94.00 89.75 to 96.86 98.21 96.51 to 99.23
HCV CAP/CTM HCVa 100.00 99.20 to 100.00 100.00 98.06 to 100.00
CAP/CTM HCVb 100.00 99.20 to 100.00 100.00 98.07 to 100.00
HepaTrioa 99.13 97.78 to 99.76 100.00 98.06 to 100.00
HepaTriob 99.13 97.79 to 99.76 100.00 98.06 to 100.00
Abbreviations: CAP/CTM, CobasH AmpliPrep/CobasH TaqManH; HBV, hepatitis B virus; HCV, hepatitis C virus; CI, confidence interval.
aSensitivity and specificity were calculated after excluding the cases with indeterminate final diagnosis (See Table 2).
bThe diagnostic performance was estimated on the assumption that the evaluated assay yielded correct results for the indeterminate cases.
doi:10.1371/journal.pone.0049106.t003
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PCR. However, detailed principle of the READ is undisclosed by
the manufacturer.
Meanwhile, the HepaTrio demonstrated well-agreed results
with those by widely used CAP/CTM assays, especially for the
detection of HCV RNA. This test also showed sensitivity and
specificity greater than 99.0% for detecting HCV infection from
patients suspected of having acute hepatitis, and the test yielded
positive results for HAV RNA in anti-HAV IgM-positive samples.
The sensitivity of the HepaTrio test for HBV infection from the
same subjects was 93.8%, and thus improvement is required.
Interestingly, the Ct with the HepaTrio test correlated well with
the viral load. Therefore, the Ct of this assay may be used as a
proxy for viral load when quantitative PCR tests are not available.
Together with the ability to detect three hepatitis viruses
concurrently, the HepaTrio test is advantageous in that the
minimum amount of sample required per test is as small as
500 mL. The minimum sample volumes required for the CAP/
CTM HBV test v2.0 and the CAP/CTM HCV test,
respectively, are 500 mL and 850 mL, excluding the dead
volume. Hence, about three times more quantity of sample is
needed for the CAP/CTM assays than for the HepaTrio test
when testing for both HBV and HCV. However, the CAP/
CTM tests still have the advantage of quantitative determina-
tion of viral nucleic acids.
In our results for HBV, the median Ct of the eight (1.2% among
all cases) HepaTrio false-positive cases was 13.15 (first to third
quartiles, 12.55 to 13.45; cutoff, 14.0), and all of these cases were
HCV infection with a median HCV RNA level of 1.066105 IU/
mL. Thus, a Ct for HBV DNA around the cutoff could be false-
positives, and these may be due to interference in the detection of
signals from different fluorophores or from cross-reaction during
the amplification of nucleic acids. Both possible causes could be an
inherent limitation of a multiplex assay, and need to be resolved.
Although we could not obtain more detailed information on the
above-mentioned READ technology because the manufacturer
has not made this information public, it is also a real-time PCR
principle and we expect that this technology can be technically
improved more by further researches.
The median Ct from the HepaTrio test for the 12 (1.9% among
all) HBV false-negative cases was 17.23 (first to third quartiles,
15.35 to 19.70), and the median HBV DNA level in these cases
was 107 IU/mL (first to third quartiles, 50.6 to 714 IU/mL).
There were also four (0.6% among all) HCV false-negative cases
with the HepaTrio test. The median HCV RNA concentration in
those four cases was 126 IU/mL. Therefore, the false-negative
results on the HepaTrio test could be due to the lower analytical
sensitivity of this assay compared to that of the CAP/CTM assays.
The lower limits of detection (LOD) suggested by the manufac-
turer are 20 IU/mL for HBV and 30 IU/mL for HCV, which are
similar or a little higher compared to those of the CAP/CTM
assays. Considering the low virus levels in those false-negative
cases, the HepaTrio was able to detect most of cases with high or
usual viral loads, thus this assay may have good sensitivity when
assaying samples from typical hepatitis patients. However,
specimens with various concentrations of HBV or HCV can be
encountered in a clinical laboratory, thus the HepaTrio test would
be more useful when the analytical sensitivity for detecting HBV
DNA is improved.
Table 4. Summary of HBV and HCV coinfection cases detected by the HepaTrio and/or the CAP/CTM assays.
CAP/CTM HepaTrio Serologic testsa PCRb Final diagnosis
Coinfection
detected by
N (%) of
cases HBV HCV HBV HCV
HepaTrio
HAV HBsAg Anti-HBc Anti-HBs
Anti-
HCV
Anti-HAV
IgM HBV HCV HBV HCV Coinfection
HepaTrio alone 3 (0.46) Neg Pos Pos Pos Neg Neg Pos Neg Pos Neg or NT Pos Pos Pos Pos Yes
7 (1.08) Neg Pos Pos Pos Neg Neg Pos or NT Pos Pos Neg or NT Neg Pos Neg Pos No
1 (0.15) Pos Neg Pos Pos Neg Pos Pos Neg NT NT Pos NT Pos Ind Ind
6 (0.93) Neg Pos Pos Pos Neg Neg or NT NT Pos or NT Pos Neg or NT NT Pos Ind Pos Ind
CAP/CTM alone 1 (0.15) Pos Pos Neg Pos Neg Neg Pos Neg Pos NT Pos Pos Pos Pos Yes
2 (0.31) Pos Pos Neg Pos Neg Neg Pos Pos Pos Neg or NT Neg Pos Neg Pos No
1 (0.15) Pos Pos Neg Pos Neg NT NT NT Pos NT NT Pos Ind Pos Ind
Both 3 (0.46) Pos Pos Pos Pos Neg Pos Pos Neg Pos NT Pos Pos Pos Pos Yes
1 (0.15) Pos Pos Pos Pos Neg Neg NT Neg Pos NT NT Pos Ind Pos Ind
Abbreviations: HBV, hepatitis B virus; HCV, hepatitis C virus; CAP/CTM, CobasH AmpliPrep/CobasH TaqManH; HAV, hepatitis A virus; PCR, polymerase chain reaction; Pos,
positive; Neg, negative; NT, not tested; Ind, indeterminate.
aSerologic test results between one month before and after sample collection were referenced when the results were consistent at two or more separated time points.
bFollow-up CAP/CTM HBV or HCV tests within a month.
doi:10.1371/journal.pone.0049106.t004
Table 5. Diagnostic performance of the HepaTrio test for
detecting HBV and HCV infections from a total of 100
hemodialysis patients.
Parameter HBV HCV
Prevalence (%) 3.0 6.0
Sensitivity (%)a 100.0 (29.2 to 100.0) 83.3 (35.9 to 99.6)
Specificity (%)a 92.8 (85.7 to 97.0) 100.0 (96.2 to 100.0)
PPV (%)a 30.0 (6.7 to 65.2) 100.0 (47.8 to 100.0)
NPV (%)a 100.0 (96.0 to 100.0) 98.9 (94.3 to 100.0)
Correct classification (%)a 93.0 (86.1 to 97.1) 99.0 (94.6 to 100.0)
Misclassification (%)a 7.0 (2.9 to 13.9) 1.0 (0.0 to 5.4)
Positive LR 13.86 ‘
Negative LR 0.00 0.17
Abbreviations: HBV, hepatitis B virus; HCV, hepatitis C virus; PPV, positive
predictive value; NPV, negative predictive value; LR, likelihood ratio.
aData are shown as % (95% confidence interval).
doi:10.1371/journal.pone.0049106.t005
A Novel Multiplex PCR for Hepatitis Diagnosis
PLOS ONE | www.plosone.org 7 November 2012 | Volume 7 | Issue 11 | e49106
In this study, a total of seven HBV and HCV coinfection cases
were found by both or either the HepaTrio test and the CAP/
CTM assays, and thus the HBV and HCV coinfection rate in our
population was 1.1%, which is lower than that reported by some
previous studies [9–11]. These differences are likely the result of
differences in the populations and in the methods utilized for
detecting coinfection between the studies. In our seven coinfection
cases, the median serum level of HBV DNA was 5.286102 IU/
mL and that of HCV RNA was 4.676104 IU/mL. Therefore,
most HBV and HCV coinfection cases seem to be caused by acute
HCV superinfection in chronic HBV carriers since Korea has a
high prevalence of chronic hepatitis B. In contrast to our results, a
previous study reported 40 cases of fulminant/subfulminant
hepatitis, five (12.5%) of which were acute coinfection with
HBV and HCV, and three (7.5%) had HCV superinfection [26].
Another study also reported a higher acute coinfection rate (9.4%)
than HCV superinfection rate (3.1%) of chronic hepatitis B among
25 patients with fulminant/subfulminant hepatitis [27]. True
diagnoses for nine cases in the present study, in which both HBV
and HCV were positive by the HepaTrio test and/or the CAP/
CTM assays, could not be identified because of insufficient
evidence. Thus, the HBV and HCV coinfection rate in our
population might actually be higher than indicated by our results.
The HepaTrio test showed high sensitivity and NPV for
detecting HBV infection as well as high specificity and PPV for the
diagnosis of HCV infection in an independent high-risk popula-
tion. However, PPV for HBV infection was low likely due to the
low prevalence (3.0%) of HBV infection in the evaluated
population and relatively small size of the population as well as
the false-positive results. Although PPV is not intrinsic to the test
and depends on the prevalence of a target disease, the current
version of the HepaTrio test would need to be improved -
especially for the detection of HBV when the test is intended to be
used as a tool for screening hepatitis. A recent study on 353
hemodialysis patients also reported similar prevalence of HBV or
HCV infection (4.5% and 8.5%, respectively) [28]. Further large-
scale studies with high-risk subjects are needed to confirm the
usefulness of the HepaTrio test in the population screening setting.
In addition, considering diagnostic accuracy as well as cost-
effectiveness, studies on the advantages of the multiplex PCR assay
over the widely used serologic tests for the diagnosis of hepatitis
would also be necessary.
Results from an assay detecting viruses could be affected by the
genotypes of the viruses. Although the genotypes of the detected
HBV were not further identified, the most prevalent HBV
genotype in Korea was C2, which accounted for 98.1% of the
total HBV cases in a recent domestic study [29]. Similar to our
data on the HCV genotypes, genotypes 1b and 2a were the two
most common types of HCV in a previous study, accounting for
virtually equal proportions, and other genotypes were extremely
rare [30]. Therefore, our data could be regarded as obtained from
the HBV genotype C and HCV genotypes 1 and 2. Further
evaluation with genotype-determined cases may be helpful for
assessing the clinical performance of the HepaTrio test according
to the HBV and HCV genotypes.
In our pilot study, the HepaTrio qualitative real-time PCR test
demonstrated good clinical performance for the concurrent
detection of the three hepatitis viruses, and results from the
HepaTrio test agreed well with those of the widely used CAP/
CTM quantitative HBV and HCV assays, although this new assay
would require improvement in the detection of HBV infections.
This test would be used as an ancillary tool for the diagnosis of
hepatitis when a patient is suspected to having hepatitis rather
than as a screening test. As a multiplex assay, the usefulness of this
new test also would need to be further evaluated by comparing its
cost-effectiveness and diagnostic performance with those of
serologic tests in the concurrent screening of acute hepatitis A, B
and C.
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